TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01280643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies
Study: NCT04258306

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pure resveratrol
Description: resveratrol extracted from Polygonum cuspidatum resveratrol (98%).
Study: NCT03930173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine
Description: A single dose of 18F-fluciclovine will be administered intravenously for PET/CT imaging. The standard 10 mCi dose will be used for this study.
Study: NCT01280643

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies
Study: NCT03683017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse 2.0
Description: Patients are given OrthoPulse 2.0, an extended OrthoPulse device with no zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPulse 2.1
Description: Patients are given OrthoPulse 2.1, an extended OrthoPulse device with zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign 3.5 Day Wear
Description: Patients are are fitted with sets of clear orthodontic Aligners by a qualified Principal Investigator (PI) using a ClinCheck plan by Align Technology. Aligners are worn for approximately 22 hours a day, and switched every 3.5 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign 3.5 Day Wear
Description: Patients are are fitted with sets of clear orthodontic Aligners by a qualified Principal Investigator (PI) using a ClinCheck plan by Align Technology. Aligners are worn for approximately 22 hours a day, and switched every 3.5 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Orthodontic Appliances (Braces)
Description: Patients are fitted with a set of brackets and wires, as per standard orthodontic treatment by a qualified Principal Investigator (PI).
Study: NCT03237715

Intervention type: OTHER
Intervention: Assessment of unbound bilirubin levels
Description: Collection of residual blood for measurement of unbound bilirubin

Intervention type: OTHER
Intervention: Assessment of unbound bilirubin levels
Description: Collection of residual blood for measurement of unbound bilirubin
Study: NCT02238158

Intervention type: DRUG
Intervention: Atrovent® inhalets
Study: NCT01280643

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies
Study: NCT00571038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Led
Description: Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
Study: NCT03930173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT of the brain
Description: Each subject will undergo 18F-fluciclovine PET/CT of the brain which will be performed ≤ 30 days from equivocal MRI brain
Study: NCT00021099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study: NCT00571038

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Seminar
Description: Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
Study: NCT02551822

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sacral neuromodulator
Description: The Implanted Pulse Generator will be set via randomization to continuous vs cycling stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sacral neuromodulator
Description: The Implanted Pulse Generator will be set via randomization to continuous vs cycling stimulation.
Study: NCT05887050

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: Blend of chromium, amla fruit extract, and citrus bioflavonoids

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin tablet
Study: NCT01908478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Study: NCT02675608

Intervention type: BIOLOGICAL
Intervention: Influenza Virus Vaccine
Description: On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.

Intervention type: BIOLOGICAL
Intervention: Influenza Virus Vaccine
Description: On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.

Intervention type: BIOLOGICAL
Intervention: Influenza Virus Vaccine
Description: On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.

Intervention type: BIOLOGICAL
Intervention: Influenza Virus Vaccine
Description: On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.

Intervention type: BIOLOGICAL
Intervention: Influenza Virus Vaccine
Description: On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
Study: NCT04138446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure in climate chamber
Description: Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure in climate chamber
Description: Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure in climate chamber
Description: Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure in climate chamber
Description: Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure in climate chamber
Description: Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Altitude exposure in climate chamber
Description: Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.
Study: NCT02057172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
Study: NCT03868202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Transdermal Product
Description: Hormone replacement therapy will be given to postmenopausal women for up to 1 month.
Study: NCT02057172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Liraglutide is a GLP-1 agonist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03954821

Intervention type: DEVICE
Intervention: prefabricated insoles
Study: NCT02889211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling Task
Study: NCT03961100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib 200 mg (R)
Description: Reference formulation (R): entrectinib hard capsules
Study: NCT02889211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling Task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling Task
Study: NCT03961100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib 200 mg (T)
Description: Test formulation (T): entrectinib HPMC capsules
Study: NCT02990169

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CATS tonometer prism
Description: IOP tonometer prism for assessment of intraocular pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann Tonometer prism
Description: IOP tonometer prism for assessment of intraocular pressure
Study: NCT04147312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fufang E'Jiao Jiang
Description: Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo containing low-dose fufang E'Jiao Jiang
Description: placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
Study: NCT02340299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nHFOV
Description: Extubation to ventilator-derived nHFOV using binasal prongs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: Extubation to ventilator-derived nCPAP using binasal prongs
Study: NCT03645668

Intervention type: DRUG
Group type: OTHER
Intervention: Meropenem Injection
Description: Different administration types between two groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Injection
Description: Different administration types between two groups
Study: NCT01659112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization
Description: A 6-week (3 days a week) exercise intervention including progressive core exercises was performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional upper extremity rehabilitation
Description: A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional upper extremity rehabilitation
Description: A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.
Study: NCT01339351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Group by Teleconference
Description: 10 sessions
Study: NCT01280643

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies
Study: NCT05235191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone tablets
Description: The intervention with the active drug (methadone) will start with the dose of 1 tablet (5 mg) twice a day (every 12 hours) and titrated on subsequent visits up to the maximum dose of 6 tablets a day (totaling 30 mg divided into 2 daily doses to facilitate therapeutic adherence).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
Study: NCT01504321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxonidine
Description: 0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated lactose powder
Study: NCT02526069

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy
Description: An application based on Acceptance and Commitment Therapy
Study: NCT04067362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food containing dietary fiber
Description: commercially available chicory root flour and chicory root fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food containing dietary fiber
Description: commercially available chicory root flour and chicory root fiber

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: food containing dietary fiber
Description: commercially available chicory root flour and chicory root fiber
Study: NCT02449239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vicinium
Description: Intravesical administration
Study: NCT01945489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (BOTOX®) injected into the detrusor.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (BOTOX®) injected into the detrusor.

Intervention type: DRUG
Group type: OTHER
Intervention: Normal saline
Description: Normal saline (placebo) injected into the detrusor.
Study: NCT01550419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The smell and shape of placebo are the same as atorvastatin
Study: NCT03323489

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Celiac Plexus Radiosurgery
Description: patients will receive a single radiation treatment of 25 Gy directed towards the celiac surgery, and at the physician's discretion also abutting tumor
Study: NCT01275066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110 Weekly
Description: BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110 Every Other Week
Description: BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
Study: NCT03455465

Intervention type: OTHER
Intervention: Community Health Worker Assessment
Description: Participants will be approached by a community health worker who will ask them to complete an assessment of needs and offer to enroll them in post-discharge services to help address the needs identified.
Study: NCT02235779

Intervention type: OTHER
Group type: OTHER
Intervention: Transbronchial lung cryobiopsy
Study: NCT01347437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive STEPS
Description: This intervention is given to patients in the experimental condition only. The Positive STEPS intervention-developed by our team-is based on general principles of cognitive-behavioral therapy as well as more specific principles of motivational interviewing32,33 and problem solving therapy. Informational, problem solving, and cognitive-behavioral STEPS are targeted over 5, in-person, intervention sessions with a PhD-level counselor. The intervention will also include a series of short videos related to the topics that the Positive STEPS intervention covers with participants. Participants in the experimental condition can also choose to receive text messages sent to their cell phone to remind them to take their medication.
Study: NCT02889211

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gambling Task
Study: NCT04778826

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphadenectomy
Description: radical bloc dissection of all mediastinal lymph node stations

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphadenectomy
Description: radical bloc dissection of all mediastinal lymph node stations
Study: NCT03634930

Intervention type: BEHAVIORAL
Intervention: observation
Description: Observation of growth, infant bodycomposition, 24h-drinkingvolume

Intervention type: BEHAVIORAL
Intervention: observation
Description: Observation of growth, infant bodycomposition, 24h-drinkingvolume
Study: NCT02630303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED-RL Phototherapy
Description: The maximum recommended starting dose (MSRD) (160 J/cm2) will be administered to Group 1's LED-RL phototherapy randomized subjects and the LED-RL dose will be escalated in subsequent groups using the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2). Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mock Therapy
Description: Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit and only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks.
Study: NCT01915173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose tablets
Study: NCT03808298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment D
Description: Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment D
Description: Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.
Study: NCT01915173

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose tablets

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expanded Interview

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Interview

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Interview
Study: NCT02915653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational materials on a new diagnostic service
Description: Educational materials on a new diagnostic service

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational materials on a new diagnostic service
Description: Educational materials on a new diagnostic service
Study: NCT05771259

Intervention type: OTHER
Intervention: Assessment of knowledge and behaviour
Description: Assessment of knowledge and behaviour

Intervention type: OTHER
Intervention: Assessment of knowledge and behaviour
Description: Assessment of knowledge and behaviour
Study: NCT02464202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stereolithography tooth replica
Description: Tooth replica will be made and used for preparing the receiving tooth socket during autotransplantation
Study: NCT02262481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dydrogesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01514695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 100mcg intravenously given in 2mL syringe at start of procedure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of saline (2ml)
Study: NCT01521611

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Targeted radiotherapy
Description: Yttrium-90 labelled anti-CD66 monoclonal antibody.